TRINETRA › Sectors › Healthcare
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — share price, P/E and fundamentals
Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM) closed at ₹215.00 on 30 Oct 2026, -2.1% over one year, against a 52-week range of ₹155.00 – ₹264.50.
In the quarter ended 30 Sept 2026 (consolidated, filed 28 Oct 2026) it reported revenue of ₹96 cr and net profit of ₹12 cr, a 12.8% net margin; revenue grew 29.4% and profit fell 2.3% year on year.
On four consecutive filed quarters its trailing P/E is 31.2; since 18 Aug 2025 its own P/E has ranged from 20.8 to 37.3 (median 30.1), and today's reading is higher than 58% of those 295 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 20.4%, ROCE 25.1%, debt-to-equity 0.00, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 50% of 64 sector peers; PBT margin higher than 47% of 64 sector peers; ROE higher than 77% of 64 sector peers.
Key figures
| Last close | ₹215.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.9% / +7.9% / -2.1% |
| 52-week low – high | ₹155.00 – ₹264.50 |
| Market capitalisation | ₹1,420 cr |
| Trailing P/E | 31.2 |
| Price / book | 5.83 |
| EV / EBITDA | 19.9 |
| Earnings yield | 3.2% |
| TTM EPS | ₹6.89 |
| TTM net profit | ₹45 cr |
| Quarter revenue | ₹96 cr |
| Quarter net profit | ₹12 cr |
| Net margin | 12.8% |
| Revenue growth (YoY) | +29.4% |
| Profit growth (YoY) | -2.3% |
| Return on equity | 20.4% |
| ROCE | 25.1% |
| Debt / equity | 0.00 |
| Current ratio | 3.54 |
| Free cash flow | ₹25 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹1.5 cr |
Against Healthcare peers
| Metric | JAGSNPHARM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 12.75 | 12.89 | 50 |
| PBT margin | 17.04 | 17.68 | 47 |
| ROE | 20.43 | 13.87 | 77 |
| ROCE | 25.14 | 17.26 | 78 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 14.26 | -0.87 | 67 |
| Cash conversion | 1.00 | 1.25 | 32 |
| Trailing P/E | 31.22 | 43.26 | 23 |
Questions
What is the P/E ratio of Jagsonpal Pharmaceuticals Limited?
Jagsonpal Pharmaceuticals Limited's trailing P/E is 31.2, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 18 Aug 2025 its P/E has ranged 20.8–37.3.
What were Jagsonpal Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Jagsonpal Pharmaceuticals Limited reported revenue of ₹96 cr and net profit of ₹12 cr (consolidated), filed with the exchange on 28 Oct 2026.
What is Jagsonpal Pharmaceuticals Limited's ROE?
Return on equity is 20.4% based on the balance sheet dated 30 Sept 2026.
Does Jagsonpal Pharmaceuticals Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is JAGSNPHARM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, JAGSNPHARM traded between ₹155.00 and ₹264.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.